On the heels of Keytruda's approval in first-line lung cancer, the drugmaker kicked off an unbranded campaign raising awareness about biomarkers.
BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA
The risk of fraud is also very real, especially in an industry that already faces privacy and compliance challenges, one expert says.
A California lawmaker reintroduces drug-pricing bill; France, Poland, Spain, and Sweden lobby to host EMA; drug stocks fall after Trump's comments
Pharma can reach physicians within the EHR, but they must send the right message at the right time, she said at an MM&M event.
Wilson will succeed founder and CEO John Seng.
This is W2O Group's third acquisition since a private-equity firm took an investment in May.
The bill now heads to President Obama's desk. He is expected to sign the sweeping piece of legislation.
Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine
The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.
Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.
Prices of Viagra and Cialis triple since 2010; AstraZeneca's Tagrisso slows lung-cancer progression compared to chemo; Novo Nordisk to limit price increases
The Roche veteran says that people who work in digital health need to touch others in a meaningful way.
The agency is owned by High Road Capital Partners. Sophy Regelous, the company's chief operating officer, will now lead the agency.
The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy
However, the rate of drug spending slowed compared to last year, according to an analysis by the CMS.
The search-engine giant says that one in 20 online searches are related to healthcare, and more users are using mobile to consume media.
Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies
Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.
Valeant doesn't plan to offload Salix; heart docs back Califf as commish; Saunders says pricing issues aren't affected by election
The bill includes two provisions that would address drugmakers' calls for clarity on sharing off-label information with payers and regulators.
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey
Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.
The bill includes provisions to investigate the usefulness of off-label information but will no longer exempt drugmakers from reporting CME payments.
The drugmaker still views Instagram as a viable marketing platform, however.
Trump selects Price as head of HHS; Warren criticizes 21st Century Cures; GSK CEO says companies will have to get used to making less money
The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.
J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe
A new survey found that U.S. pharma marketers prefer using social media and mobile apps to reach healthcare providers.
Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China
The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.
Most physicians said EHRs have negatively impacted their communication with a patients.
Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials
The drugstore chain added drug effectiveness reviews and other information from PatientsLikeMe to its website.
Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel
Chicago requires pharma rep to have licenses, Acorda CEO backs Califf to remain FDA commish, high-prescribing medicare docs are on the rise
As part of the acquisition, 160 AccentHealth employees will join ContextMedia, which has a staff of about 500 people.
Former Valeant and Philidor execs arrested; at least 1 million enroll in 2017 exchange plans; mobile game helps scientists study dementia
Drugmakers can do a better job of organizing dosing information, safety information, and clinical data on their brand websites, a new survey found.
The largest group of U.S. physicians said drug pricing needs to align with the broader healthcare industry's drive for value.
The AMA votes in favor of value-based drug pricing; Amgen says insurers are balking at PCSK9 inhibitor prices; docs aren't focused on prices when prescribing
New clinical data showed that Repatha, a PCSK9 inhibitor, reduced plaque in arteries when combined with a statin.
"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.
The CMS spent more on Harvoni than any other drug; Novartis considers selling Alcon; the EMA recommends approval of Lantus biosimilar
The programmatic advertising technology company also hired Chris Neuner as SVP and GM of digital health.
Pfizer expanded its humanitarian efforts by providing the Prevnar 13 vaccine at a low price and donating proceeds to aid groups.
J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader
Insurers and pharmacy benefit managers already have a sophisticated understanding of clinical data, the industry argued.
Trump says he will reform the FDA; pharmaceutical M&A expected to pick up; superbug causing infections in cystic-fibrosis patients
The FDA asked questions about the risks and benefits of allowing off-label communications.
Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions
But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.
Trump, a critic and supporter of pharma, wins election; pharma's futures rise in election's wake; drug-pricing measure in California likely to be defeated
The partnership will span ApotheCom's offices around the world, including those in the U.S., U.K., and Asia.
FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast
The health system is one of the largest in the country. Most of Ascension's hospitals, Ragone says, used to operate almost independently from each other and the company's headquarters.
Bayer submits Stivarga to FDA for liver-cancer indication; emails show FDA's divisiveness over Duchenne drug approval; insurers want new president to address ACA financial risks
Here are 5 statistics about off-label promotion ahead of the FDA's public hearing this week.
Spurred by recent lawsuits, the FDA is scheduled to hold a two-day hearing this week on whether to allow drugmakers more latitude in promoting therapies off-label.
Supernus Pharmaceuticals received an untitled letter over a promotional video for Oxtellar XR.
Pharma may face price-collusion charges; FDA approval team can't fill vacancies; OPDP issues letter over promo video
Sprout investors sue Valeant; FDA raises safety concerns for Cempra's experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients
With about 70 million users in six million health-related groups, drugmakers have tremendous opportunity to reach key audiences on Facebook. Here's how.
BMS and Pfizer outspent Johnson & Johnson two-to-one in advertising for their oral anticoagulant last year.
Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences
Mylan was slammed by people unable to afford its lifesaving EpiPen injection device following a price hike — its response was seen as too little, too late.
Facebook opens up to pharma; Pfizer nixes PCSK9 inhibitor in development; Cardinal Health cuts forecast on dwindling price increases
Takeda launched four new superheroes whose lives have been touched by inflammatory bowel disease (IBD), with the help of PR agency Ketchum.
Shares decline on news drugmakers will limit price hikes; AstraZeneca said it will leave UK if country doesn't pay for new drugs; Astellas acquires Ganymed
The new TV spot was developed with CNN and Edelman.
Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle
The number of warning and untitled letters has dropped in recent years. Only four letters have been sent so far this year, compared to 28 in 2012.
BIO released a video explaining drug costs; the FDA commits to shorter generic approval process; Kaléo to launch EpiPen competitor
The FDA responded to criticism from industry about its proposed research of DTC animation.
Tom Jones joined Ketchum after serving as head of healthcare at Makovsky.
While VR is only just getting started, some marketers are already embracing its potential to offer an immersive experience for far-off future campaigns.
Novartis CEO said pricing environment to worsen; Purdue Pharma offered PBM rebates to get around oxycodone prior authorization; Express Scripts subpoenaed
Merck Consumer Health CMO Atilla Cansun also talks about about why the company is focused on preparing society for an average lifespan of 100 years.
Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health
Denise Strauss, formerly VP of cardiovascular marketing at Boehringer Ingelheim, will oversee the drugmaker's marketing activities.
Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.
Voters are set to vote on Proposition 61, which would allow state agencies to pay the same prices for drugs that the VA department pays.
GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus
Lawmakers ask for information about price of leukemia drug; Abbott writes down losses from Mylan stake; CVS Health focused on role as health brand
Excedrin's #DebateHeadache was inspired by complaints the brand noticed during the first presidential debate in September.
Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug
More acquisitions, less IPOs, and more non-traditional stakeholders are among key findings from StartUp Health and Rock Health about the state of digital health funding.
Roche gets FDA approval for immunotherapy Tecentriq; insurers are sued for discrimination; the FDA proposes yanking generic ADHD drugs from market
In the United States, people over 50 are often stereotyped as complacent, set in their ways and extremely loyal to their preferred brands, but a new study released Tuesday by Ketchum found that the opposite is true.
Pfizer to start selling Remicade biosimilar in November; The Medicines Co.'s PCSK9 inhibitor heads to Phase-III trials; J&J's Q3 growth bolstered by autoimmune drugs
Guidemark Health, Bluespire, Bluespire Senior Living, and Ariad Communications will merge under a new entity.
Doctors Without Borders refuses free Pfizer vaccines; Valeant to raise prices of certain drugs; two urologists advocate for overactive bladder drugs
Cleveland Clinic CEO Toby Cosgrove said at the PRWeek Conference that the pharmaceutical industry has a responsibility to manage drug costs without the government stepping in
Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo
Aetna inks value-based deal with Merck in diabetes; new research claims co-pay cards increased drug spend; Xarelto data not affected by device
The partnership allows Sermo to expand the reach of its research initiatives and Everyday Health to scale its targeted advertising on the social platform.
Valeant is under fire for another price hike; Novartis and Queen Latifah raise awareness about heart failure; critics take aim at co-pay programs
The company hired Christine Cassiano, who is charged with preparing the communications strategy for the drugmaker's experimental cancer therapy.
Merck doled out more than $2 million to target doctors in the first half of the year, while BMS spent only $863,000.
- BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists
- Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.
- Five things for pharma marketers to know: Wednesday, December 7, 2016
- Matt Brown leaves Guidemark Health after merger falls through
- Five things for pharma marketers to know: Monday, December 5, 2016
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Women in senior industry roles improve connections with patients, execs say